Introduction of an Infliximab Biosimilar (CT-P13)- A Five-Year Budget Impact Analysis for the Treatment of Rheumatoid Arthritis in Ireland
Nov 1, 2013, 00:00 AM
10.1016/j.jval.2013.08.1465
https://www.valueinhealthjournal.com/article/S1098-3015(13)03370-6/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1307
First Page :
A558
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)03370-6&doi=10.1016/j.jval.2013.08.1465